Ajer Jeffrey Robert's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Aug 17, 2023
- Accession no.
- 0001048477-23-000039
- Filed
- Aug 17, 2023
- Trade date
- Apr 28-Aug 16, 2023
- Filing delay
- 111 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $450.0K. It was filed 111 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ajer Jeffrey RobertCIK 0001557533 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | AGrant or awardAcquired | +318 | $66.88 | +$21,267.84 | 65,804 | Direct | |
| Aug 16, 2023 | Common Stock | SSaleDisposed | −5,000 | $90.00 | −$450,000 | 60,804 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.